^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug Class:PD-L1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

    Published date:
    12/15/2022
    Excerpt:
    Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 1.4….TMB ≥ 10 should be interpreted as high and correlates with a clinical benefit to PD-1 inhibitors
    DOI:
    10.1200/JCO.22.02328